Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 22, 2018
Pharmacy Choice - News - Pharmaceutical Development - January 22, 2018

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

1/22/18 - "Crystalline Forms of (N, N-Diethylcarbamoyl)methyl Methyl (2e)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use" in Patent Application Approval...
"Crystalline Forms of methyl Methyl but-2-Ene-1, 4- Dioate, Methods of Synthesis and Use" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Mao, Chen; Scheuerman, Randall A.; Karaborni, Sami, filed on September 6, 2017, was made available online on January 11
1/22/18 - "Methods of Treating Pulmonary Sarcoidosis" in Patent Application Approval Process (USPTO 20170368150)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventor Burns, Barry, filed on September 4, 2015, was made available online on January 11, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Gotham Biopharmaceuticals Inc..
1/22/18 - "Mutated Factor X Polypeptides and Uses Thereof for the Treatment of Haemophilia" in Patent Application Approval Process (USPTO 20170369861)
By a News Reporter-Staff News Editor at Clinical Trials Week A patent application by the inventors CHRISTOPHE, Olivier; LENTING, Petrus; DENIS, Cecile, filed on January 6, 2016, was made available online on January 11, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not be
1/22/18 - "Use of Levocetirizine and Montelukast in the Treatment of Anaphylaxis" in Patent Application Approval Process (USPTO 20170368059)
By a News Reporter-Staff News Editor at Clinical Trials Week A patent application by the inventor May, Bruce Chandler, filed on July 13, 2017, was made available online on January 11, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company or institu
1/22/18 - Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy
By a News Reporter-Staff News Editor at Biotech Business Week Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, announced its outlook for the coming year, including its plans to report topline results in February from its pivotal Phase 3 PALISADE trial of AR101 for peanu
1/22/18 - AIT Therapeutics Announces Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria Patients
AIT Therapeutics a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with serious lung infections and pulmonary hypertension, today announced positive data at Day 81, the end of its NO-NTM Abscessus clinical trial. Additionally, the anti-microbial effect of NO is apparent with qPCR...
1/22/18 - AIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients
AIT Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with serious lung infections and pulmonary hypertension, today announced positive data at Day 81, the end of its NO-NTM Abscessus clinical trial. The Company previously announced positive preliminary data...
1/22/18 - Albert Einstein College of Medicine Details Findings in Clinical Trials and Studies (Minimally Invasive Separation Surgery with Intraoperative...
Albert Einstein College of Medicine Details Findings in Clinical Trials and Studies. According to news reporting out of Bronx, New York, by NewsRx editors, research stated, "The treatment of spinal metastasis consists of algorithms combining surgical and radiation modalities. Our news journalists obtained a quote from the research from the Albert E
1/22/18 - Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura
Anthera Pharmaceuticals today announced a positive outcome of the second, pre-specified interim futility analysis for the RESULT Phase 3 clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency. Are You Aware of the FDA's Plans for 2018? The post Anthera Announces Positive Outcome of Second Interim Futility Analysis in the
1/22/18 - Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this Quarter
Anthera Pharmaceuticals, Inc. today announced a positive outcome of the second, pre-specified interim futility analysis for the RESULT Phase 3 clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency. About Anthera Pharmaceuticals Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on...
1/22/18 - Appili Therapeutics Licenses Bioterrorism Vaccine Rights
By a News Reporter-Staff News Editor at Bioterrorism Week Appili Therapeutics Inc., an anti-infective drug development company, announced it has signed a licence agreement with the National Research Council of Canada to develop ATI-1701, a vaccine to protect against Francisella tularensis, a potential bioterrorism agent that causes tularemia.
1/22/18 - ArTara Therapeutics Announces Addition of Randall Marshall, MD as Chief Medical Officer
Dr. Marshall will join as a co-founder of ArTara to provide scientific and medical leadership for research and business development activities. Prior to joining ArTara, Dr. Marshall led Retrophin, Inc.' s development of fosmetpantotenate, a replacement therapy for PKAN, an ultra-rare neurodegenerative disease. Under Dr. Marshall's leadership the pr
1/22/18 - Athenex Announces Encouraging Early Clinical Efficacy and Safety Data of Oraxol in Clinical Trial for the Treatment of Breast Cancer
Athenex, a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced encouraging preliminary efficacy and safety data of Oraxol in the treatment of breast cancer in a pharmacokinetics and Phase I/II clinical trial of 24 pati
1/22/18 - Athenex Announces Encouraging Results of the First Cohort of Phase I Clinical Trial of Oraxol and CYRAMZA (Ramucirumab) Combination Treatment in Gastric Cancer
Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the completion of the first cohort of patients in its Phase 1 b clinical trial of Oraxol plus CYRAMZA in gastric cancer patients that failed previ
1/22/18 - Australia and Asia Pacific offer international biotech industry a wealth of clinical trial and costs benefits
By a News Reporter-Staff News Editor at Clinical Trials Week Australia and the Asia Pacific are fast becoming the destination of choice for the over US $140 billion international biotech industry1, with considerable research incentives, supportive regulatory environments and affordable trial costs available. "Like any business, biotech companies
1/22/18 - Baxter Announces U.S. FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
Baxter International Inc., a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration approval of Bivalirudin in 0.9 percent Sodium Chloride Injection. "The approval of bivalirudin demonstrates how Baxter brings its innovative technologies together with medicines in ways that help promote..
1/22/18 - Baxter Announces U.S. FDA Approval of Ready-To-Use Cardiovascular Medication Bivalirudin; First presentation of bivalirudin in frozen, premixed, ready-to-use formulation
DEERFIELD, Ill.- Baxter International Inc., a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration approval of Bivalirudin in 0.9 percent Sodium Chloride Injection. "The approval of bivalirudin demonstrates how Baxter brings its innovative technologies together with medicines in ways th
1/22/18 - BERG Announces FDA Orphan-Drug Designation of BPM31510 for the Treatment of Pancreatic Cancer
"The FDA's orphan-drug designation marks an important milestone for BERG," said Niven R. Narain, BERG President and Chief Executive Officer. "We look forward to working closely with the FDA and other regulatory authorities to advance the clinical development of this therapeutic and map out the most effective match for treatment of pancreatic cance
1/22/18 - Best Practices' Study Examines How Pharmaceutical Industry is Navigating the New Scientific Publications Landscape
By a News Reporter-Staff News Editor at Clinical Trials Week Biopharmaceutical organizations rely on scientific publications to inform the medical community about critical clinical trial data. It is the data from early phases of drug development that critical stakeholders such as physicians and payers learn about new products. and the information
1/22/18 - Bio-Rad Gains Additional U.S. FDA Clearances for Blood Typing Products, Expanding its Offering for the Blood Testing Market
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced that it has received 510 clearance from the U.S. Food and Drug Administration for the IH- Incubator L and IH- Centrifuge L instruments to be used with the full range of Bio-Rad s IH- System Gel Reagents for manual blood typing m
1/22/18 - Boston Scientific Receives U.S. FDA Approval for Spectra WaveWriter Spinal Cord Stimulator System
By a News Reporter-Staff News Editor at Pharma Business Week Boston Scientific Corporation announced that the U.S. Food and Drug Administration has approved the Spectra WaveWriter? Spinal Cord Stimulator System. It is the first and only system approved by the FDA to simultaneously provide paresthesia-based and sub-perception therapy.
1/22/18 - Cardiovascular Ultrasound System Market" Top Key Companies Toshiba Medical Systems Corporation, Siemens AG, GE Company and Forecast by 2024: Global Cardiovascular Ultrasound System Market By Test Type (Transthoracic Echocardiogram, Transesophageal Ec
Pune, India 01/22/2018 The Global Cardiovascular Ultrasound System Market accounted to USD 1.27 billion in 2016, at a CAGR of 5.4% during the forecast period of 2017 to 2024.. The report includes market shares of global cardiovascular ultrasound system market for global, Europe, North America, Asia Pacific and South America. Major Market Driv
1/22/18 - Cellectar Biosciences to Participate at Noble Capital Markets Fourteenth Annual Investor Conference
Cellectar Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that company management will be participating in Noble Capital Markets Fourteenth Annual Investor Conference taking place January 29-30, 2018 at the W Hotel, F
1/22/18 - CEO, Brady Grainer, From BioCorRxInc. Paves Pathway Towards Possible FDA Approval on Stock Day Podcast; Aims to Fight Opioid Crisis
Noting that the stock price of the Company has doubled since the last appearance Mr. Jolly allows Mr. Grainer the opportunity to discuss the latest developments of the long-sought FDA approval. Mr. Grainer introduces the two operational portions of the Company; the substance abuse treatment portion as well as a pharmaceutical research and developme
1/22/18 - CFDA issues guidance on drug review and approval transparency
With hopes to improve transparency, China FDA issued draft guidance on the public disclosure of information related to its review and approval of drug applications. The guidelines say the agency is responsible for disclosing information regarding an application's acceptance, the review and approval process and result of the review through a public
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415